Repare Therapeutics Inc. (RPTX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
RPTX Chart
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2025. “During the first quarter of 2025 we continued our efforts to create long-term value for our shareholders via partnering and by advancing our novel pipeline programs,” said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. “W.
Repare Therapeutics Announces Leadership Transitions
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that Steve Forte, Executive Vice President and Chief Financial Officer, has been appointed as President and Chief Executive Officer and to the Board of Directors effective April 11, 2025. He will serve in this new role in addition to his current role as the Company's Chief Financial Officer. Lloyd M. Segal has res.
What Makes Repare Therapeutics (RPTX) a New Buy Stock
Repare Therapeutics (RPTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Repare Therapeutics Inc. Dividends
Repare Therapeutics Inc. Earnings
| 14 May 2025 Date | | - Cons. EPS | - EPS |
| 3 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 7 Aug 2024 Date | | - Cons. EPS | - EPS |
| 7 May 2024 Date | | - Cons. EPS | 0.3 EPS |
| 14 May 2025 Date | | - Cons. EPS | - EPS |
| 3 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 7 Aug 2024 Date | | - Cons. EPS | - EPS |
| 7 May 2024 Date | | - Cons. EPS | 0.3 EPS |
Repare Therapeutics Inc. (RPTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Repare Therapeutics Inc. ever had a stock split?
Repare Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Steve Forte CPA CEO | NASDAQ (NGS) Exchange | 760273102 Cusip |
| CA Country | 129 Employees | - Last Dividend | - Last Split | 19 Jun 2020 IPO Date |
Overview
Repare Therapeutics Inc. is a pioneering force in the realm of precision oncology, operating principally in Canada and the United States. The company stands out thanks to its innovative synthetic lethality approach towards the development of cancer therapeutics. Synthetic lethality occurs when the combination of mutations in two or more genes leads to cell death, whereas a mutation in just one gene does not, and Repare Therapeutics leverages this principle to target and kill cancer cells while sparing healthy ones. Their cutting-edge SNIPRx platform, which is both proprietary and CRISPR-enabled, spans genome-wide operations to discover, validate, and cultivate a robust pipeline of SL-based therapeutics. These focus particularly on genomic instability issues, such as DNA damage repair. Since its inception in 2016, Repare Therapeutics has cemented its presence in the industry, partnering with several prestigious organizations and continuously advancing in its mission from its headquarters in Montréal, Canada.
Products and Services
Camonsertib (RP-3500): Serving as the lead product candidate, Camonsertib is an oral small molecule inhibitor currently undergoing Phase ½ development. Its therapeutic focus lies in treating solid tumors that exhibit specific DNA damage repair-related genomic alterations. This product exemplifies Repare Therapeutics’ commitment to harnessing synthetic lethality for oncological precision medicine.
Lunresertib (RP-6306): This promising product is a PKMYT1 Inhibitor under Phase 1 clinical trial. Its target demographic includes patients with tumors characterized by genetic alterations manifested through CCNE1 amplification. Lunresertib represents an innovative approach to targeting cancer’s genetic vulnerabilities.
RP-1664: Another critical element of Repare Therapeutics' pipeline, RP-1664, is an oral PLK4 inhibitor. Also in Phase 1 clinical trial, this product is designed to exploit the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors. It's a strategic advancement in the understanding and treatment of cancer at the genetic level.
RP-3467: An inhibitor of the polymerase theta adenosinetriphosphatase (ATPase), RP-3467 is currently under development as a SL target associated with BRCA mutations and other genomic alterations. This product candidate showcases Repare Therapeutics' focus on using synthetic lethality to address specific genetic configurations that promote cancer proliferation.
Aside from its innovative pipeline, Repare Therapeutics has established significant license and collaboration agreements. These partnerships include agreements with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co. Additionally, a clinical study and collaboration agreement with Debiopharm aims to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer, emphasizing the collaborative and forward-thinking approach of Repare Therapeutics Inc. in the fight against cancer.
Contact Information
